These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25009656)

  • 1. Downregulation of CD40 expression contributes to the accumulation of myeloid-derived suppressor cells in gastric tumors.
    Shen J; Chen X; Wang Z; Zhang G; Chen W
    Oncol Lett; 2014 Aug; 8(2):775-780. PubMed ID: 25009656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.
    Pan PY; Ma G; Weber KJ; Ozao-Choy J; Wang G; Yin B; Divino CM; Chen SH
    Cancer Res; 2010 Jan; 70(1):99-108. PubMed ID: 19996287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer.
    Hu X; Bardhan K; Paschall AV; Yang D; Waller JL; Park MA; Nayak-Kapoor A; Samuel TA; Abrams SI; Liu K
    J Biol Chem; 2013 Jun; 288(26):19103-15. PubMed ID: 23677993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
    Chaib M; Sipe LM; Yarbro JR; Bohm MS; Counts BR; Tanveer U; Pingili AK; Daria D; Marion TN; Carson JA; Thomas PG; Makowski L
    Cancer Lett; 2022 Apr; 531():98-108. PubMed ID: 35074498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.
    Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH
    J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells.
    Xiao P; Wan X; Cui B; Liu Y; Qiu C; Rong J; Zheng M; Song Y; Chen L; He J; Tan Q; Wang X; Shao X; Liu Y; Cao X; Wang Q
    Oncoimmunology; 2016; 5(1):e1063772. PubMed ID: 26942079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
    Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
    Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages.
    Valencia JC; Erwin-Cohen RA; Clavijo PE; Allen C; Sanford ME; Day CP; Hess MM; Johnson M; Yin J; Fenimore JM; Bettencourt IA; Tsuneyama K; Romero ME; Klarmann KD; Jiang P; Bae HR; McVicar DW; Merlino G; Edmondson EF; Anandasabapathy N; Young HA
    Cancer Res; 2021 Dec; 81(23):5977-5990. PubMed ID: 34642183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine IL6-Mediated Activation of the STAT3-DNMT Axis Silences the TNFα-RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor Cells.
    Smith AD; Lu C; Payne D; Paschall AV; Klement JD; Redd PS; Ibrahim ML; Yang D; Han Q; Liu Z; Shi H; Hartney TJ; Nayak-Kapoor A; Liu K
    Cancer Res; 2020 Aug; 80(15):3145-3156. PubMed ID: 32554751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
    Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
    J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
    Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
    Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
    Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
    Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
    Horikawa N; Abiko K; Matsumura N; Hamanishi J; Baba T; Yamaguchi K; Yoshioka Y; Koshiyama M; Konishi I
    Clin Cancer Res; 2017 Jan; 23(2):587-599. PubMed ID: 27401249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of PLCγ2-β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer.
    Capietto AH; Kim S; Sanford DE; Linehan DC; Hikida M; Kumosaki T; Novack DV; Faccio R
    J Exp Med; 2013 Oct; 210(11):2257-71. PubMed ID: 24127488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.
    Waight JD; Netherby C; Hensen ML; Miller A; Hu Q; Liu S; Bogner PN; Farren MR; Lee KP; Liu K; Abrams SI
    J Clin Invest; 2013 Oct; 123(10):4464-78. PubMed ID: 24091328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
    Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
    J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
    van Hooren L; Georganaki M; Huang H; Mangsbo SM; Dimberg A
    Oncotarget; 2016 Jul; 7(31):50277-50289. PubMed ID: 27385210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells.
    Liu F; Li X; Lu C; Bai A; Bielawski J; Bielawska A; Marshall B; Schoenlein PV; Lebedyeva IO; Liu K
    Oncotarget; 2016 Dec; 7(51):83907-83925. PubMed ID: 27880732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.